Posttraumatic Stress Disorder Therapeutics (PTSD) - Pipeline Assessment and Market Forecasts to 2019



Summary



GlobalData, the industry analysis specialist, has released its new report, “Posttraumatic Stress Disorder Therapeutics (PTSD) - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Post-Traumatic Stress Disorder (PTSD) Therapeutics market. The report identifies the key trends shaping and driving the global Post-Traumatic Stress Disorder (PTSD) Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Post-Traumatic Stress Disorder (PTSD) Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.



Scope


The report provides information on the key drivers and challenges of the Post-Traumatic Stress Disorder (PTSD) Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Post-Traumatic Stress Disorder (PTSD) Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Post-Traumatic Stress Disorder (PTSD) Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Post-Traumatic Stress Disorder (PTSD) Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Post-Traumatic Stress Disorder (PTSD) Therapeutics market



Reasons to buy


The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Post-Traumatic Stress Disorder (PTSD) Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Post-Traumatic Stress Disorder (PTSD) Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Post-Traumatic Stress Disorder (PTSD) Therapeutics market landscape? – Identify, understand and capitalize.

Table Of Contents

1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Posttraumatic Stress Disorder Therapeutics - Introduction 8
2.1 Disease Overview 8
2.2 Epidemiology 9
2.2.1 Prevalence 9
2.2.2 Pharmacoeconomic Burden 11
2.2.3 Quality of Life (QoL) 12
2.3 Etiology and Pathophysiology 12
2.3.2 Risk Factor 18
2.3.3 Co-morbidities 19
2.4 Signs and Symptoms 20
2.4.1 Re-experiencing Symptoms 20
2.4.2 Avoidance symptoms 20
2.4.3 Hyperarousal Symptoms 20
2.5 Diagnosis 22
2.5.1 Diagnosis Criteria 22
2.5.2 Psychobiologic Approaches 25
2.6 Treatment and Management Options 26
2.6.1 Non-pharmacological Treatment 28
2.6.2 Pharmacological Treatment 28
2.6.3 The US 31
2.6.4 Europe 32
2.7 Referral Pathway 33
2.8 GlobalData Pipeline Report Guidance 34
3 Posttraumatic Stress Disorder Therapeutics - Market Characterization 35
3.1 Overview 35
3.2 Posttraumatic Stress Disorder Therapeutics Market Size (2006-2011) - Global 35
3.3 Posttraumatic Stress Disorder Therapeutics Market Forecast (2011-2019) - Global 37
3.4 Posttraumatic Stress Disorder Therapeutics Market Size (2006-2011) - The US 38
3.5 Posttraumatic Stress Disorder Therapeutics Market Forecast (2011-2019) - The US 39
3.6 Posttraumatic Stress Disorder Therapeutics Market Size (2006-2011) - France 40
3.7 Posttraumatic Stress Disorder Therapeutics Market Forecast (2011-2019) - France 41
3.8 Posttraumatic Stress Disorder Therapeutics Market Size (2006-2011) - Germany 42
3.9 Posttraumatic Stress Disorder Therapeutics Market Forecast (2011-2019) - Germany 43
3.10 Posttraumatic Stress Disorder Therapeutics Market Size (2006-2011) - Italy 44
3.11 Posttraumatic Stress Disorder Therapeutics Market Forecast (2011-2019) - Italy 45
3.12 Posttraumatic Stress Disorder Therapeutics Market Size (2006-2011) - Spain 46
3.13 Posttraumatic Stress Disorder Therapeutics Market Forecast (2011-2019) - Spain 47
3.14 Posttraumatic Stress Disorder Therapeutics Market Size (2006-2011) - The UK 48
3.15 Posttraumatic Stress Disorder Therapeutics Market Forecast (2011-2019) - The UK 49
3.16 Posttraumatic Stress Disorder Therapeutics Market Size (2006-2011) - Japan 50
3.17 PTSD Therapeutics Market Forecast (2011-2019) - Japan 51
3.18 Drivers and Barriers for the Posttraumatic Stress Disorder Therapeutics Market 52
3.18.1 Drivers for the Posttraumatic Stress Disorder Therapeutics Market 52
3.18.2 Barriers for the Posttraumatic Stress Disorder Therapeutics Market 52
3.19 Opportunity and Unmet Need Analysis 53
3.20 Key Takeaway 54
4 Posttraumatic Stress Disorder Therapeutics - Competitive Assessment 55
4.1 Overview 55
4.2 Strategic Competitor Assessment 55
4.3 Product Profiles for the Major Marketed Products in the Posttraumatic Stress Disorder Therapeutics Market 56
4.3.1 Selective Serotonin Reuptake Inhibitors (SSRIs) 56
4.3.2 Paxil (paroxetine) 57
4.3.3 Zoloft (sertraline) 58
4.3.4 Serotonin-Norepinephrine Reuptake Inhibitors (SNRI) 59
4.3.5 Atypical Antipsychotics 60
4.4 Key Takeaway 60
5 Posttraumatic Stress Disorder Therapeutics - Pipeline Assessment 61
5.1 Overview 61
5.2 Strategic Pipeline Assessment 61
5.3 Posttraumatic Stress Disorder Therapeutics Pipeline - Pipeline by Phases of Development 62
5.3.1 Posttraumatic Stress Disorder Therapeutics - Phase III Pipeline 62
5.3.2 Posttraumatic Stress Disorder Therapeutics - Phase II Pipeline 63
5.3.3 Posttraumatic Stress Disorder Therapeutics - Phase I Pipeline 63
5.3.4 Posttraumatic Stress Disorder Therapeutics - Pre-clinical Pipeline 63
5.3.5 Posttraumatic Stress Disorder Therapeutics - Discovery Pipeline 64
5.3.6 Technology Trends Analytic Framework 64
5.4 Posttraumatic Stress Disorder Therapeutics Market -Pipeline by Mechanism of Action 66
5.5 Molecule Profile for Promising Drugs under Clinical Development 67
5.5.1 Avlocardyl (propranolol) 67
5.6 Key Takeaway 67
6 Posttraumatic Stress Disorder Therapeutics - Clinical Trials Mapping 68
6.1 Clinical Trials by Region/Country (US, EU5 and Japan) 68
6.2 Clinical Trials by Phase 69
6.3 Clinical Trials by Trial Status 70
6.4 Prominent Sponsors 71
6.5 Top Companies Participating in Posttraumatic Stress Disorder Therapeutics Clinical Trials 72
7 Posttraumatic Stress Disorder Therapeutics - Strategic Assessment 73
7.1 Key Events Impacting the Future Market 73
7.2 Posttraumatic Stress Disorder Therapeutics: Implications for Future Market Competition 74
8 Posttraumatic Stress Disorder Therapeutics - Future Players 75
8.1 Introduction 75
8.2 Company Profiles 76
8.2.1 Synosia Therapeutics/Biotie Therapies Corp. 76
8.2.2 Columbia Northwest Pharmaceuticals 77
8.2.3 Marinus Pharmaceuticals, Inc. 77
8.2.4 Nanotherapeutics, Inc. 78
9 Posttraumatic Stress Disorder Therapeutics - Licensing and Partnership Deals 79
10 Posttraumatic Stress Disorder Therapeutics - Appendix 80
10.1 Market Definitions 80
10.2 Abbreviations 80
10.3 Bibliography 81
10.4 Research Methodology 83
10.4.1 Coverage 83
10.4.2 Secondary Research 84
10.4.3 Forecasting 84
10.4.4 Primary Research 86
10.4.5 Expert Panel Validation 87
10.5 Contact Us 87
10.6 Disclaimer 87

List of Tables

Table 1: Prevalence Rates of Posttraumatic Stress Disorder by Country/Region 9
Table 2: Frequency (%) of Lifetime Co-morbidities in Patients with Posttraumatic Stress Disorder* 19
Table 3: DSM-IV Diagnostic Criteria for Posttraumatic Stress Disorder 23
Table 4: ICD-10 Diagnostic Criteria for Posttraumatic Stress Disorder 24
Table 5: Medications for Posttraumatic Stress Disorder - Indications and Contraindications 30
Table 6: Posttraumatic Stress Disorder Therapeutics Market, Global, Revenue ($m), 2006-2011 36
Table 7: Posttraumatic Stress Disorder Therapeutics Market, Global, Forecast ($m), 2011-2019 37
Table 8: Posttraumatic Stress Disorder Therapeutics Market, Global, Revenue ($m), 2006-2011 38
Table 9: Posttraumatic Stress Disorder Therapeutics Market, The US, Forecasts ($m), 2011-2019 39
Table 10: Posttraumatic Stress Disorder Therapeutics Market, France, Revenue ($m), 2006-2011 40
Table 11: Posttraumatic Stress Disorder Therapeutics Market, France, Forecasts ($m), 2011-2019 41
Table 12: Posttraumatic Stress Disorder Therapeutics Market, Germany, Revenue ($m), 2006-2011 42
Table 13: Posttraumatic Stress Disorder Therapeutics Market, Germany, Forecasts ($m), 2011-2019 43
Table 14: Posttraumatic Stress Disorder Therapeutics Market, Italy, Revenue ($m), 2006-2011 44
Table 15: Posttraumatic Stress Disorder Therapeutics Market, Italy, Forecasts ($m), 2011-2019 45
Table 16: Posttraumatic Stress Disorder Therapeutics Market, Spain, Revenue ($m), 2006-2011 46
Table 17: Posttraumatic Stress Disorder Therapeutics Market, Spain, Forecasts ($m), 2011-2019 47
Table 18: Posttraumatic Stress Disorder Therapeutics Market, The UK, Revenue ($m), 2006-2011 48
Table 19: Posttraumatic Stress Disorder Therapeutics Market, The UK, Forecasts ($m), 2011-2019 49
Table 20: Posttraumatic Stress Disorder Therapeutics Market, Japan, Revenue ($m), 2006-2011 50
Table 21: Posttraumatic Stress Disorder Therapeutics Market, Japan, Forecasts ($m), 2011-2019 51
Table 22: SSRIs Used for Treatment of Posttraumatic Stress Disorder 56
Table 23: SNRIs used in treatment of Posttraumatic Stress Disorder 59
Table 24: Posttraumatic Stress Disorder Therapeutics - Phase III Pipeline, 2012 62
Table 25: Posttraumatic Stress Disorder Therapeutics - Phase II Pipeline, 2012 63
Table 26: Posttraumatic Stress Disorder Therapeutics - Phase I Pipeline, 2012 63
Table 27: Posttraumatic Stress Disorder Therapeutics - Pre-clinical Pipeline, 2012 63
Table 28: Posttraumatic Stress Disorder Therapeutics - Discovery Pipeline, 2011 64
Table 29: Posttraumatic Stress Disorder Therapeutics - Clinical Trials by Country, 2011 68
Table 30: Posttraumatic Stress Disorder Therapeutics -- Clinical Trials by Phase, 2011 69
Table 31: Posttraumatic Stress Disorder Therapeutics - Clinical Trials by Status 70
Table 32: Posttraumatic Stress Disorder Therapeutics - Overall Sponsors, 2011 71
Table 33: Posttraumatic Stress Disorder Therapeutics - Most Prominent Sponsors, 2011 71
Table 34: Posttraumatic Stress Disorder Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011 72
Table 35: Biotie Therapies, CNS Pipeline 2012 76
Table 36: Columbia Northwest Pharmaceuticals, CNS Pipeline 2012 77
Table 37: Marinus Pharmaceuticals, Inc., CNS Pipeline 2012 78
Table 38: Nanotherapeutics, Inc., CNS Pipeline 2012 78
Table 39: Posttraumatic Stress Disorder Therapeutics, Global, Deals, 2010-2012 79

List of Figures

Figure 1: Time Course and Posttraumatic Stress Disorder Subtypes 8
Figure 2: Key Opinion Leader Insights, Prevalence of Posttraumatic Stress Disorder in the US, Germany and the UK 10
Figure 3: Posttraumatic Stress Disorder Prevalence in Adults in the US 10
Figure 4: Posttraumatic Stress Disorder Treatment Rate in the US 11
Figure 5: Factors Associated with the Development of Posttraumatic Stress Disorder 12
Figure 6: Genetic Factors Associated in Patients with Posttraumatic Stress Disorder 13
Figure 7: HPA-axis Pathway, Stress Responses 14
Figure 8: Posttraumatic Stress Disorder, Stress Responses 15
Figure 9: Neuroendocrine Features in Patients with Posttraumatic Stress Disorder 15
Figure 10: Neurotransmitter Features in Patients with Posttraumatic Stress Disorder 17
Figure 11: Neuroanatomic Features in Patients with Posttraumatic Stress Disorder 18
Figure 12: Co-morbidities Associated with Posttraumatic Stress Disorder 19
Figure 13: Symptoms of Posttraumatic Stress Disorder 21
Figure 14: Key Opinion Leader Insights, Diagnosis of Posttraumatic Stress Disorder in the US, Germany and the UK 26
Figure 15: Key Opinion Leader Insights, Guidelines for Posttraumatic Stress Disorder in the US, Germany and the UK 26
Figure 16: Algorithm for the Diagnosis and Treatment of Posttraumatic Stress Disorder 27
Figure 17: The US:Treatment Guideline for Posttraumatic Stress Disorder 31
Figure 18: Key Opinion Leader Insights, Treatment of Posttraumatic Stress Disorder in the US, Germany and the UK 32
Figure 19: Referral Pathway for Posttraumatic Stress Disorder 33
Figure 20: Key Opinion Leader Insights, Referral Pathway for Posttraumatic Stress Disorder in the US, Germany and the UK 33
Figure 21: Posttraumatic Stress Disorder Therapeutics Market, Global, Revenue ($m), 2006-2011 35
Figure 22: Posttraumatic Stress Disorder Therapeutics Market, Global, Forecast ($m), 2011-2019 37
Figure 23: Posttraumatic Stress Disorder Therapeutics Market, the US, Revenue ($m), 2006-2011 38
Figure 24: Posttraumatic Stress Disorder Therapeutics Market, The US, Forecast ($m), 2011-2019 39
Figure 25: Posttraumatic Stress Disorder Therapeutics Market, France, Revenue ($m), 2006-2011 40
Figure 26: Posttraumatic Stress Disorder Therapeutics Market, France, Forecast ($m), 2011-2019 41
Figure 27: Posttraumatic Stress Disorder Therapeutics Market, Germany, Revenue ($m), 2006-2011 42
Figure 28: Posttraumatic Stress Disorder Therapeutics Market, Germany, Forecast ($m), 2011-2019 43
Figure 29: Posttraumatic Stress Disorder Therapeutics Market, Italy, Revenue ($m), 2006-2011 44
Figure 30: Posttraumatic Stress Disorder Therapeutics Market, Italy, Forecast ($m), 2011-2019 45
Figure 31: Posttraumatic Stress Disorder Therapeutics Market, Spain, Revenue ($m), 2006-2011 46
Figure 32: Posttraumatic Stress Disorder Therapeutics Market, Spain, Forecast ($m), 2011-2019 47
Figure 33: Posttraumatic Stress Disorder Therapeutics Market, The UK, Revenue ($m), 2006-2011 48
Figure 34: Posttraumatic Stress Disorder Therapeutics Market, The UK, Forecast ($m), 2011-2019 49
Figure 35: Posttraumatic Stress Disorder Therapeutics Market, Japan, Revenue ($m), 2006-2011 50
Figure 36: Posttraumatic Stress Disorder Therapeutics Market, Japan, Forecast ($m), 2011-2019 51
Figure 37: Key Opinion Leader Insights, Current Unmet Needs for Posttraumatic Stress Disorder in the US, Germany and the UK 53
Figure 38: Opportunity and Unmet Need for Posttraumatic Stress Disorder Therapeutics Market 54
Figure 39: Key Opinion Leader Insights, Limitations of the Currently Available Treatment Options for Posttraumatic Stress Disorder in the US, Germany and the UK 55
Figure 40: Posttraumatic Stress Disorder Therapeutics - Strategic Competitor Assessment, 2011 56
Figure 41: Key Opinion Leader Insights, Research for Future Treatment Options for Posttraumatic Stress Disorder in the US, Germany and the UK 61
Figure 42: Posttraumatic Stress Disorder Therapeutics - Pipeline by Phase of Development, 2012 62
Figure 43: Posttraumatic Stress Disorder Therapeutics - Technology Trends Analytics Framework, 2012 64
Figure 44: Posttraumatic Stress Disorder Therapeutics - Technology Trends Analytics Framework - Description, 2012 65
Figure 45: Posttraumatic Stress Disorder Therapeutics - Pipeline by Mechanism of Action, 2012 66
Figure 46: Clinical Trial Details of Avlocardyl (Propranolol) 67
Figure 47: Posttraumatic Stress Disorder Therapeutics - Clinical Trials by Country, 2011 68
Figure 48: Posttraumatic Stress Disorder Therapeutics - Clinical Trials by Phase, 2011 69
Figure 49: Posttraumatic Stress Disorder Therapeutics - Clinical Trials by Status, 2011 70
Figure 50: Posttraumatic Stress Disorder Therapeutics - Overall Sponsors, 2012 71
Figure 51: Posttraumatic Stress Disorder Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011 72
Figure 52: Posttraumatic Stress Disorder Therapeutics Market, Drivers and Restraints 2011 73
Figure 53: Implications for Future Market Competition in Posttraumatic Stress Disorder Market, 2011 74
Figure 54: Posttraumatic Stress Disorder Therapeutics Market - Pipeline by Company, 2012 75
Figure 55: GlobalData Market Size Estimation 85
Figure 56: GlobalData Market Forecasting Model 86

Companies mentioned
Synosia Therapeutics/Biotie Therapies Corp.
Columbia Northwest Pharmaceuticals
Marinus Pharmaceuticals, Inc.
Nanotherapeutics, Inc.

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

Inflammation - Pipeline Review, H1 2014

Inflammation - Pipeline Review, H1 2014

  • $ 2 500
  • Company report
  • June 2014
  • by Global Markets Direct

Inflammation - Pipeline Review, H1 2014 Summary Global Markets Direct's, ‘Inflammation - Pipeline Review, H1 2014', provides an overview of the Inflammation's therapeutic pipeline. This report provides ...

Corcept Therapeutics Incorporated - Product Pipeline Review - 2014

Corcept Therapeutics Incorporated - Product Pipeline Review - 2014

  • $ 1 500
  • Company report
  • April 2014
  • by Global Markets Direct

Corcept Therapeutics Incorporated - Product Pipeline Review - 2014 Summary Global Markets Direct's, ‘Corcept Therapeutics Incorporated - Product Pipeline Review - 2014', provides an overview of the Corcept ...

Pharmaceutical in United States: ImmunoCellular Therapeutics, Ltd. – Product Pipeline Review – H2 2011

Pharmaceutical in United States: ImmunoCellular Therapeutics, Ltd. – Product Pipeline Review – H2 2011

  • $ 1 500
  • Company report
  • May 2014
  • by Global Markets Direct

- Product Pipeline Review - H2 2011” provides a detailed overview on the ImmunoCellular Therapeutics, Ltd.’s research and development focus. The report includes information on current developmental ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.